 Chemical Structure.png)
Physicochemical Properties
| Molecular Formula | C17H12F4N2O2 |
| Molecular Weight | 352.28 |
| Exact Mass | 352.083 |
| CAS # | 2275774-60-0 |
| PubChem CID | 137465182 |
| Appearance | White to off-white solid powder |
| LogP | 4.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 2 |
| Heavy Atom Count | 25 |
| Complexity | 529 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | O1[C@@H](C)C(C2=CC=C(C3=CC=C(F)C=C3)C(C(F)(F)F)=C2)=NNC1=O |
| InChi Key | JNTJTCXFIXNXDV-VIFPVBQESA-N |
| InChi Code | InChI=1S/C17H12F4N2O2/c1-9-15(22-23-16(24)25-9)11-4-7-13(14(8-11)17(19,20)21)10-2-5-12(18)6-3-10/h2-9H,1H3,(H,23,24)/t9-/m0/s1 |
| Chemical Name | (6S)-5-[4-(4-fluorophenyl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-1,3,4-oxadiazin-2-one |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Brain cancer (especially glioma, more specifically glioblastoma and astrocytoma), breast cancer (especially ductal carcinoma and adenocarcinoma), cervical cancer, AML (especially erythroleukemia), lung cancer (especially NSCLC adenocarcinoma) and SCLC, skin cancer (especially melanoma), esophageal cancer (especially squamous cell carcinoma), ovarian cancer (especially teratoma fetal cancer, adenocarcinoma), pancreatic cancer, and prostate cancer are all effectively inhibited by BAY 2666605 (Example 135) [1]. |
| ln Vivo | In a mouse xenograft model of human cancer, treatment with BAY 2666605 (5 mg/kg; oral; twice daily) showed antitumor effectiveness [1]. |
| References |
[1]. Dihydrooxadiazinones. WO2019025562A1. |
| Additional Infomation | SLFN12-PDE3A Complex Inducer BAY 2666605 is an orally bioavailable agent that triggers the formation of a complex of the two proteins Schlafen family member 12 (SLFN12) and phosphodiesterase 3A (PDE3A), with potential antineoplastic activity. Upon oral administration, SLFN12-PDE3A complex inducer BAY2666605 triggers the formation of the SLFN12-PDE3A complex. This stabilizes SLFN12 and alters the expression of a set of genes that regulate cell survival, death, and proliferation. This suppresses cell cycle progression and induces apoptosis in cancer cells that specifically express elevated levels of both of these proteins. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~250 mg/mL (~709.66 mM) |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8387 mL | 14.1933 mL | 28.3865 mL | |
| 5 mM | 0.5677 mL | 2.8387 mL | 5.6773 mL | |
| 10 mM | 0.2839 mL | 1.4193 mL | 2.8387 mL |